SOUTH
SAN FRANCISCO, Calif., July 5, 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq:
RIGL) today announced that it has granted awards pursuant to the
Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the
Compensation Committee of Rigel's Board of Directors and granted as
an inducement material to employees' entering into employment with
Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Specifically, Rigel granted 247,400 stock options to six
non-executive employees vesting over four years with a one-year
cliff.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology
company dedicated to discovering, developing and providing novel
therapies that significantly improve the lives of patients with
hematologic disorders and cancer. Founded in 1996, Rigel is based
in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products, visit
www.rigel.com.
Contact for Investors & Media
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301870372.html
SOURCE Rigel Pharmaceuticals, Inc.